Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zai Lab Ltd (HK:9688)
HKEX:9688
Holding HK:9688?
Track your performance easily
9688 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$10.56 - HK$24.40
Previous CloseHK$16.32
Volume651.60K
Average Volume (3M)2.68M
Market Cap
HK$16.22B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Nov 05, 2024EPS Estimate
-HK$0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding979,087,430
10 Day Avg. Volume2,184,947
30 Day Avg. Volume2,677,409
Standard Deviation0.18
R-Squared0.39
Alpha-0.00812
Financial Highlights & Ratios
Price to Book (P/B)16.82
Price to Sales (P/S)15.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$43.47Price Target Upside166.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Zai Lab Ltd News
PremiumCompany Announcements
Zai Lab Grants New Shares to Incentivize Employees
PremiumCompany Announcements
Zai Lab’s Revenue Soars, Losses Narrow in Interim Report
PremiumCompany Announcements
Zai Lab Limited to Approve Interim Financial Results
PremiumCompany Announcements
Zai Lab Rewards Employees with Equity Incentive
PremiumCompany Announcements
Zai Lab Reports Strong Growth and Pipeline Expansion
PremiumCompany Announcements
Zai Lab Files Quarterly Report with SEC
PremiumCompany Announcements
Zai Lab to Announce Mid-Year 2024 Financial ResultsOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
8.74% Mutual Funds
3.68% Other Institutional Investors
87.58% Public Companies and
Individual Investors
9688 FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
Zai Lab Ltd lowest stock price was HK$10.56 and its highest was HK$24.40 in the past 12 months.
What is Zai Lab Ltd’s market cap?
Currently, no data Available
When is Zai Lab Ltd’s upcoming earnings report date?
Zai Lab Ltd’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were Zai Lab Ltd’s earnings last quarter?
Zai Lab Ltd released its earnings results on Aug 06, 2024. The company reported -HK$0.64 earnings per share for the quarter, missing the consensus estimate of -HK$0.56 by -HK$0.08.
Is Zai Lab Ltd overvalued?
According to Wall Street analysts Zai Lab Ltd’s price is currently Undervalued.
Does Zai Lab Ltd pay dividends?
Zai Lab Ltd does not currently pay dividends.
What is Zai Lab Ltd’s EPS estimate?
Zai Lab Ltd’s EPS estimate is -HK$0.61.
How many shares outstanding does Zai Lab Ltd have?
Zai Lab Ltd has 996,087,650 shares outstanding.
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Zai Lab Ltd reported an EPS of -HK$0.64 in its last earnings report, missing expectations of -HK$0.56. Following the earnings report the stock price went up 6.122%.
Which hedge fund is a major shareholder of Zai Lab Ltd?
Currently, no hedge funds are holding shares in HK:9688
---
Zai Lab Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$43.47 (166.33% Upside)
HK$43.47 (166.33% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.82%
12-Months-Change
Fundamentals
Return on Equity
-36.54%
Trailing 12-Months
Asset Growth
-9.15%
Trailing 12-Months
Company Description
Zai Lab Ltd
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. The other product candidate includes Fugan, ZL-2302, and ZL-1101. The company operates through the segment being Developing and commercializing proprietary therapeutics.
---
9688 Stock 12 Month Forecast
Average Price Target
HK$43.47
▲(166.33% Upside)
Technical Analysis
Best Analysts Covering 9688
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a buy rating last month
Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---